Pilatus Biosciences to Present New COPD Data for PLT012 at ERS 2026
Pilatus Biosciences to Present Preclinical Data Highlighting PLT012’s Disease-Modifying Potential in COPD at ERS International Congress 2026 Pilatus Biosciences, a clinical-stage biopharmaceutical company focused on developing innovative metabolic checkpoint immunotherapies…
Seaport Therapeutics Reports Q2 2026 Financial Results and Clinical Progress
Seaport Therapeutics Reports Second Quarter 2026 Results, Highlights Positive Clinical Progress and Strengthened Financial Position Following IPO Seaport Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for…
Korsana Biosciences Announces Executive and Board Appointments
Korsana Biosciences Strengthens Executive Leadership as KRSA-028 Advances Toward Clinical Development for Alzheimer’s Disease Korsana Biosciences, Inc., a biotechnology company focused on discovering and developing innovative therapies for neurodegenerative disorders,…
Zai Lab’s DLL3-Targeting ADC Zoci Earns FDA Orphan Drug Status
Zai Lab’s DLL3-Targeting ADC Receives FDA Orphan Drug Designation for Neuroendocrine Carcinomas Zai Lab Limited has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation…
Rocket Pharmaceuticals Reports Positive Safety Update for RP-A501 Phase 2 Trial
Rocket Pharmaceuticals Reports Positive Early Safety Update for RP-A501 Phase 2 Trial in Danon Disease Rocket Pharmaceuticals, Inc. has announced encouraging early safety results from the first three patients treated…
Polpharma Biologics Advances PB016 with FDA and EMA Regulatory Acceptance
Polpharma Biologics Advances PB016 as FDA and EMA Accept Biosimilar Applications for Review Polpharma Biologics International AG has announced a significant regulatory milestone with the acceptance of both its Biologics…
Bayer Seeks New Indication Approval for Kerendia in China
Bayer Submits New Drug Application in China to Expand Finerenone Use for Adults with Non-Diabetic Chronic Kidney Disease Bayer has announced the submission of a New Drug Application (NDA) to…
Novo Nordisk Shares Update on Phase 3 ZEUS Trial
Novo Nordisk Reports Topline Results from Phase 3 ZEUS Trial Evaluating Ziltivekimab for Cardiovascular Risk Reduction Novo Nordisk has announced topline findings from its pivotal Phase 3 ZEUS cardiovascular outcomes…
EU Approves Datroway® for First-Line Metastatic TNBC Treatment
EU Approval Positions Datroway® as the Only TROP2-Targeted Therapy with Overall Survival Benefit in First-Line Metastatic TNBC The European Commission (EC) has approved Datroway® (datopotamab deruxtecan) as a monotherapy for…
Polpharma Biologics Secures FDA and EMA Review for PB016 Biosimilar
Polpharma Biologics’ Vedolizumab Biosimilar PB016 Accepted for FDA and EMA Review, Advancing Access to Biologic Therapy for Inflammatory Bowel Disease Polpharma Biologics International AG has announced that its proposed vedolizumab…
PHC Launches Cell-IQ® CO₂ Incubators with Advanced Humidity Control
PHC Corporation of North America Launches Cell-IQ® CO₂ Incubator Series with Advanced Humidity Control and Contamination Prevention PHC Corporation of North America (PHCNA), a leading provider of PHCbi laboratory equipment…
Contineum Therapeutics Announces Second-Quarter 2026 Financial Results
Contineum Therapeutics Reports Second Quarter 2026 Financial Results and Reaffirms Clinical Development Milestones Across Inflammatory and Fibrotic Disease Pipeline Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing differentiated…